Logo

DNA

Ginkgo Bioworks Holdings, Inc.

DNA

Ginkgo Bioworks Holdings, Inc. • NYSE
$9.28 ▲ 1.87% (+0.17)
Market Cap $507.12 M
52w High $17.58
52w Low $5.00
Dividend Yield 0%
P/E -1.5
Volume 443.76K
Outstanding Shares 54.65M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $38.837M ▼ $116.052M ▲ $-80.755M ▼ -207.933% ▼ $-1.45 ▼ $-66.586M ▼
Q2-2025 $49.604M ▲ $100.323M ▼ $-60.3M ▲ -121.563% ▲ $-1.1 ▲ $-46.074M ▲
Q1-2025 $48.318M ▲ $125.239M ▼ $-90.957M ▲ -188.247% ▲ $-1.68 ▲ $-68.329M ▲
Q4-2024 $43.847M ▼ $137.831M ▲ $-107.534M ▼ -245.248% ▼ $-2.07 ▼ $-143.484M ▼
Q3-2024 $89.046M $134.263M $-56.403M -63.341% $-1.08 $-35.086M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $461.862M ▼ $1.189B ▼ $629.382M ▲ $559.783M ▼
Q2-2025 $473.691M ▼ $1.231B ▼ $618.057M ▼ $612.952M ▼
Q1-2025 $516.922M ▼ $1.293B ▼ $646.036M ▼ $647.427M ▼
Q4-2024 $561.572M ▼ $1.377B ▼ $661.391M ▼ $716.058M ▼
Q3-2024 $616.214M $1.481B $682.94M $797.943M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-80.755M ▼ $-31.606M ▲ $-72.816M ▼ $9.938M ▲ $-94.391M ▲ $-31.606M ▲
Q2-2025 $-60.3M ▲ $-40.254M ▲ $-63.888M ▲ $-98K ▲ $-105.848M ▲ $-40.292M ▲
Q1-2025 $-90.957M ▲ $-51.521M ▼ $-198.684M ▼ $-207K ▼ $-250.338M ▼ $-59.143M ▼
Q4-2024 $-107.534M ▼ $-42.435M ▲ $-13.085M ▼ $-203K ▲ $-55.796M ▲ $-56.145M ▲
Q3-2024 $-56.403M $-103.501M $-10.2M $-465K $-113.651M $-118.59M

Revenue by Products

Product Q3-2024Q4-2024Q1-2025Q2-2025
Service
Service
 $10.00M ▲$40.00M ▲$10.00M ▼$10.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue grew quickly early on but has slipped back over the last couple of years, suggesting momentum has softened and some past growth was not yet durable. The company consistently generates a healthy gross margin, meaning its core services can be delivered for much less than they charge, at least before overhead. However, spending on research, staffing, and overhead is still far higher than revenue, leading to large operating and net losses every year. These losses have narrowed somewhat from their peak, but the business is still far from break-even and remains highly dependent on external funding rather than internally generated profits.

Balance Sheet

Balance Sheet The balance sheet shows a company that started out cash-rich after going public but has been gradually drawing down that cushion. Cash has declined meaningfully over time, while total assets have shrunk as losses accumulate and investments are used up. Debt has risen compared with the early years, though it does not yet dominate the capital structure, and shareholders’ equity remains positive but has been steadily eroded by ongoing losses. The recent reverse stock split is a signal that market valuation and share price pressure have been concerns, even though it does not change the underlying economics.

Cash Flow

Cash Flow The business burns cash every year, mainly from operating activities rather than heavy capital spending. Capital expenditures are relatively modest and stable, which means the main cash outflow is funding the ongoing development of the platform and the organization around it. Free cash flow is consistently negative, indicating the company is not yet self-funding and will likely need either to keep reducing costs, grow more predictable revenue, or access additional capital over time. The overall cash trend is downward, so the pace of cash burn versus remaining cash is an important risk factor to monitor.

Competitive Edge

Competitive Edge Ginkgo is positioned as a horizontal synthetic biology platform, aiming to be the “picks and shovels” provider for many different industries rather than a single-product biotech. Its automated Foundry, large genetic Codebase, and data and AI capabilities create real barriers for smaller or less-integrated labs to match. Network effects and accumulated biological data can strengthen its position over time as more partners use the platform. That said, the field is young, competition from other contract research and platform players is intense, and the commercial model is still being proven in terms of stable, repeatable, high-margin revenue. Customer concentration, project-based work, and long timelines for partners’ products to succeed all add uncertainty to how durable the competitive position will be in practice.

Innovation and R&D

Innovation and R&D The company is highly innovation-driven, with much of its spending devoted to building and refining the Foundry, expanding the Codebase, and integrating AI and machine learning into biological design. It has a strong culture of experimentation, partnerships, and acquisitions aimed at broadening its technology stack and data assets. The shift toward more modular offerings—automation tools, data products, and fee-for-service work—shows it is adapting its model to turn deep R&D capabilities into nearer-term revenue. However, this level of R&D and platform investment is costly, and the payoffs are uncertain and often slow, depending on partners’ success and adoption of synthetic biology solutions across industries.

Summary

Overall, Ginkgo is a highly ambitious synthetic biology platform company with strong technological depth but a financially immature profile. It combines high gross margins and a differentiated tech stack with persistent operating losses, steady cash burn, and a shrinking cash cushion. The balance sheet still has support, but trends point to the need for either faster, more predictable revenue growth or tighter cost control over time. Strategically, its data-rich platform, AI integration, and broad industry reach could be powerful if customer demand scales, yet the business model remains unproven at large, sustainable scale. For now, the story is a trade-off between significant scientific and platform potential on one hand, and clear financial risk and execution uncertainty on the other.

NEWS

November 18, 2025 · 8:00 AM UTC

Ginkgo Bioworks Partners on Illinois-Led Team to Develop Innovative New Treatments for Oral Health

Read more

November 6, 2025 · 4:05 PM UTC

Ginkgo Bioworks Reports Third Quarter 2025 Financial Results

Read more

November 3, 2025 · 9:00 AM UTC

Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of DNA Molecules

Read more

November 3, 2025 · 8:00 AM UTC

Ginkgo Bioworks Awarded Project Agreement through BARDA's BioMaP-Consortium

Read more

October 31, 2025 · 8:00 AM UTC

Ginkgo Bioworks and Bayer Extend Multi-Year Strategic Partnership to Accelerate Next Generation Biological Solutions for Agriculture

Read more